Switch to:
GuruFocus has detected 6 Warning Signs with Allergan PLC $AGN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
Allergan PLC (NYSE:AGN)
Research & Development
$2,576 Mil (TTM As of Dec. 2016)

This is the expense the company spent on research and development. Allergan PLC's research and development for the three months ended in Dec. 2016 was $913 Mil. Its research and development for the trailing twelve months (TTM) ended in Dec. 2016 was $2,576 Mil.


Definition

This is the expense the company spent on research and development.

Allergan PLC Research & Development for the trailing twelve months (TTM) ended in Dec. 2016 was 403.1 (Mar. 2016 ) + 636.5 (Jun. 2016 ) + 622.8 (Sep. 2016 ) + 913.3 (Dec. 2016 ) = $2,576 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.


Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Related Terms

Gross Profit


Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

Allergan PLC Annual Data

Dec07Dec08Dec09Dec10Dec11Dec12Dec13Dec14Dec15Dec16
Research & Development 1451701972963074031916062,3592,576

Allergan PLC Quarterly Data

Sep14Dec14Mar15Jun15Sep15Dec15Mar16Jun16Sep16Dec16
Research & Development 2772374314551,261431403637623913
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK